News
Emerging Treatments for Patients with Myeloma Prove Promising Despite Obstacles
Myeloma is a complicated cancer type that can be tough to find a treatment option for which patients will respond to. However, in the past several...
Government unveils national cancer agency and $60 million injection into Pharmac
The Government has today unveiled plans to establish a national cancer agency, which will be led directly by experts of the deadly disease, and a...
Blood cancer more likely to affect relatives of people who have it, study shows
Close relatives of people with blood cancer are more likely to be diagnosed with the disease themselves, a major study has found. An international...
Suboptimal Implementation of Supportive Care in Older Patients With Multiple Myeloma
According to findings from a study published in Cancer on the utilization of specific supportive care measures in older patients with multiple...
Another myeloma drug with same target as CAR-Ts shows successful Phase II results
A Phase II study of a GlaxoSmithKline drug to treat the blood cancer multiple myeloma has been successful, the company said Friday. The London-based...
Dual CAR T-cell combination a ‘promising treatment option’ for multiple myeloma
A combination of humanized anti-CD19 and anti-B-cell maturation antigen chimeric antigen receptor T-cells has shown activity in patients with...
Government urged to expand Pharmac’s drug budget after barrage of emotional pleas from sufferers
This story was originally published on Stuff "Why does New Zealand need to reinvent the wheel?" Posed by National MP Maggie Barry, that was the...
Health Select Committee hears pleas from survivors and sufferers
This story was originally published on RNZ Politicians heard emotional pleas today from cancer survivors, people with disabilities and health...
Blood cancer patient advocacy group presents to Health Select Committee to fund life-extending treatments
Dr Ken Romeril, chief executive, Myeloma New Zealand, is appearing today before the Health Select Committee in support of their submission asking...
Dr. Nadeem on Individualizing Therapy in Multiple Myeloma
Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses individualizing...
Improved Clinical Outcomes in Relapsed/Refractory Multiple Myeloma With Daratumumab Re-Treatment
This story was originally published on the Hematology Advisor The introduction of monoclonal antibodies and immunomodulators into earlier lines of...